Epidemiology of Lung Cancer in Korea: Recent Trends

Park, Ji Young; Jang, Seung Hun

doi:10.4046/trd.2016.79.2.58

Cited by 119 publications

(128 citation statements)

References 67 publications

(94 reference statements)

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…This is much lower than the rate of EGFR mutations reported in Asian populations (Choi et al, 2013;Park & Jang, 2016) but similar to rates described by other studies in European cohorts (Giannini et al, 2016;Savic et al, 2015;Tapia et al, 2009;Van Zandwijk et al, 2007). This is much lower than the rate of EGFR mutations reported in Asian populations (Choi et al, 2013;Park & Jang, 2016) but similar to rates described by other studies in European cohorts (Giannini et al, 2016;Savic et al, 2015;Tapia et al, 2009;Van Zandwijk et al, 2007).…”

Section: Discussionsupporting

confidence: 85%

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices

et al. 2017

View full text Add to dashboard Cite

In order to improve outcomes, identification of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genes has become crucial in advanced non-small-cell lung cancer (NSCLC). The aim of the present study is to analyse time trends and frequency of testing, factors affecting testing as well as prevalence of mutations in the Swiss population. We analysed EGFR and ALK testing in a cohort of patients with newly diagnosed metastasised non-squamous NSCLC in the catchment area of the cancer registry Eastern Switzerland in the years 2008-2014. We analysed prevalence of mutations and studied clinicopathological characteristics and survival of tested and non-tested patients and of patients with and without mutations. Among 718 patients identified, 11% (51/447) harboured an EGFR mutation in the exons 18, 19 or 21 and further 12% (31/265) showed a positive test result for ALK rearrangements. In non-smokers the proportions of mutations were 31% and 23% respectively. Testing rates increased over time and reached 79% in 2014. We observed significantly lower testing rates and poorer survival in elderly, patients with limited life expectancy and patients treated at hospitals not involved in clinical research. Outcomes can be further improved in a considerable proportion of patients with advanced non-squamous NSCLC.

show abstract

Section: Discussionsupporting

confidence: 85%

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices

et al. 2017

View full text Add to dashboard Cite

show abstract

“…2 Among NSCLCs, adenocarcinoma is the most common type in Korea. 3 Despite advances in cancer treatment, treatment fails in many cases, resulting in disease progression, recurrence and metastasis. 4 One of the major reasons for treatment failure is intratumoural heterogeneity; a small number of cells have stem-cell-like properties (or stemness), and can survive treatment with common anticancer drugs.…”

Section: Introductionmentioning

confidence: 99%

Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity

et al. 2016

View full text Add to dashboard Cite

A small proportion of cancer cells have stem-cell-like properties, are resistant to standard therapy and are associated with a poor prognosis. The metabolism of such drug-resistant cells differs from that of nearby non-resistant cells. In this study, the metabolism of drug-resistant lung adenocarcinoma cells was investigated. The expression of genes associated with oxidative phosphorylation in the mitochondrial membrane was negatively correlated with the prognosis of lung adenocarcinoma. Because the mitochondrial membrane potential (MMP) reflects the functional status of mitochondria and metastasis is the principal cause of death due to cancer, the relationship between MMP and metastasis was evaluated. Cells with a higher MMP exhibited greater migration and invasion than those with a lower MMP. Cells that survived treatment with cisplatin, a standard chemotherapeutic drug for lung adenocarcinoma, exhibited increased MMP and enhanced migration and invasion compared with parental cells. Consistent with these findings, inhibition of mitochondrial activity significantly impeded the migration and invasion of cisplatin-resistant cells. RNA-sequencing analysis indicated that the expression of mitochondrial complex genes was upregulated in cisplatin-resistant cells. These results suggested that drug-resistant cells have a greater MMP and that inhibition of mitochondrial activity could be used to prevent metastasis of drug-resistant lung adenocarcinoma cells.

show abstract

“…And in South Korea, it also accounts for 12.5% of lung cancer in 2012 [4, 5]. Unfortunately, treatment is not effective in altering the high recurrence rate and short survival, regardless of the initial stage of SCLC at the diagnosis [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Park

Chung

Park

et al. 2016

Canadian Respiratory Journal

View full text Add to dashboard Cite

Purpose. Topotecan and belotecan are camptothecin derivatives that are used to treat small cell lung cancer (SCLC). This study compared the toxicities and efficacies of belotecan and topotecan monotherapies in patients with SCLC. Methods. We retrospectively reviewed data from 94 patients with SCLC (with or without prior chemotherapy) who were treated using belotecan monotherapy (n = 59, 188 cycles) or topotecan monotherapy (n = 35, 65 cycles) between September 2003 and December 2011. Results. Thrombocytopenia occurred during 42% and 61.5% of the belotecan and topotecan cycles, respectively (p = 0.007). Significant differences between belotecan and topotecan were also observed for grade 4/5 lung infection (3.2% versus 10.8%, resp.; p = 0.003), all-grade headache (3.2% versus 10.8%, resp.; p = 0.017), and grade 4/5 increased liver enzymes (0.5% versus 4.6%, resp.; p = 0.023). The median TTPDs, CSSs, and OSs were 14 months and 11.6 months (p = 0.646), 10 months and 7 months (p = 0.179), and 34.5 months and 21.4 months (p = 0.914) after belotecan and topotecan monotherapy, respectively. Conclusions. Belotecan monotherapy may be safer than topotecan monotherapy in SCLC patients. And in terms of efficacy, belotecan could be comparable to topotecan monotherapy.

show abstract

Epidemiology of Lung Cancer in Korea: Recent Trends

Cited by 119 publications

References 67 publications

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices

Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity

Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Contact Info

Product

Resources

About